Yongjin Wang

发表

Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea

I. Abe, Xiaoyun Lu, R. He, 2020, Nature Communications.

Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.

Yong Xu, Lei Zhang, Xiaoyun Lu, 2019, European journal of medicinal chemistry.

A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria

Xiaoyun Lu, Zhengqiu Li, Ke Ding, 2022, Nature Communications.

Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells.

J. Smaill, Liang Chen, A. Patterson, 2022, Journal of medicinal chemistry.

Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.

S. Xiang, Xiaoyun Lu, Zheng-chao Tu, 2022, Journal of medicinal chemistry.

JND4135, a New Type II TRK Inhibitor, Overcomes TRK xDFG and Other Mutation Resistance In Vitro and In Vivo

Xiaoyun Lu, Zheng-chao Tu, Ke Ding, 2022, Molecules.

Molecular insights into the catalytic mechanism of plasticizer degradation by a monoalkyl phthalate hydrolase

Zhi-Min Zhang, Liu Yang, Yang-yang Xu, 2023, Communications Chemistry.

Characterization of an aromatic trifluoromethyl ketone as a new warhead for covalently reversible kinase inhibitor design.

Yongheng Chen, Zheng-chao Tu, Ke Ding, 2021, Bioorganic & medicinal chemistry.

Secondary-structure switch regulates the substrate binding of a YopJ family acetyltransferase

Shuguang Yuan, L. Deslandes, Chengjun Zhu, 2021, Nature Communications.

Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations.

Ke Ding, Zhang Zhang, Zhi-Min Zhang, 2023, Journal of medicinal chemistry.